Journal Article – Implantable Drug Delivery Systems for GLP-1s Receptor Agonists. No more shots! What could go wrong?
Several companies and research groups are actively exploring implantable drug delivery systems for GLP-1 receptor agonists (GLP-1 RAs), aiming to improve patient adherence, convenience, and therapeutic outcomes. Here’s a summary of key players and motivations: Getting drugs into a human body is harder than it looks. The GLP1 need to be in the blood to […]
Journal Article – Real-world use of tirzepatide among individuals without evidence of type2 diabetes: Results from the Veradign® database
March 14, 2025 Hunter Gibble T, Chinthammit C, Ward JM, Cappell K, Sedgley R, Bonafede M, Liao B, Hankosky ER. Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database. Diabetes Obes Metab. 2025 Jun;27(6):3185-3194. doi: 10.1111/dom.16330. Epub 2025 Mar 14. PMID: 40084533; PMCID: PMC12046461. This source describes […]
Journal Article – GIPR Antagonism and GLP-1R Agonism Metabolic Effects
Gutgesell RM, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu X, Garcia-Caceres C, Cebrian-Serrano A, Douros JD, Knerr PJ, Finan B, DiMarchi RD, Sloop KW, Samms RJ, Theis FJ, Tschöp MH, Müller TD. GIPR agonism and antagonism decrease body weight […]
Journal Article – GLP1-RAs and Thyroid Cancer Risk
January 16, 2025Thyroid Vol 35, No. 1 This research article investigates the potential link between glucagon-like peptide 1 receptor agonists (GLP1-RAs), medications used for type 2 diabetes, and the risk of developing thyroid cancer. Conducted as a large, international study across multiple sites in six countries, it compared GLP1-RA users with those using dipeptidyl peptidase-4 inhibitors (DPP-4is), another class […]
Draft FDA Guidance – Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction – Guidance for Industry
Released: January 7, 2025Level 1 GuidanceDraft This draft guidance document from the U.S. Food and Drug Administration (FDA) outlines recommendations for the development of drugs and biological products intended for weight reduction and maintenance in both adult and pediatric patients with obesity or overweight and related comorbidities. It provides information on clinical trial design, including subject populations, trial size and duration, and the assessment […]
Review Article – GLP-1-Based Therapies for Diabetes, Obesity and Beyond
by Daniel J Drucker Nature Reviews Drug Discovery Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8. Epub ahead of print. PMID: 40281304. This review article discusses GLP-1-based therapies, highlighting their effectiveness for managing type 2 diabetes and obesity, including well-known drugs like semaglutide and tirzepatide. The text details the evolution […]
Healthcare News – Cigna doubles down on GLP-1 support programs with 2 new launches
The company’s health services division Evernorth is unveiling new programs in a reliable growth area: assuaging payer concerns around GLP-1 coverage. Dive Brief: This article focuses on Cigna’s strategies regarding the growing demand for GLP-1 weight loss medications. Cigna’s health services division, Evernorth, is launching two new support programs aimed at assisting patients and easing concerns for payers regarding the high […]
Breast Cancer Research – Can weight loss drugs prevent breast cancer recurrence?
That’s the question researchers aim to answer in a new, first-of-its-kind, clinical trial in North Texas By Bianca Castro • Published April 30, 2025 • Updated on April 30, 2025 at 10:52 pm Researchers in Dallas are investigating the potential of weight loss medications, specifically a drug called tirzepatide, as a novel approach to reducing the risk of breast cancer recurrence in women who are […]
Journal Article – “Body Composition Metrics as a Determinant of Trastuzumab Deruxtecan Related Toxicity and Response”
Yaacobi Peretz, S., Kessner, R., Bar, Y. et al. Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response. npj Breast Cancer 11, 38 (2025). https://doi.org/10.1038/s41523-025-00754-7 This scientific article explores the connection between a patient’s body composition and their experience with the drug trastuzumab deruxtecan (T-DXd) for metastatic breast cancer. Using computed tomography scans to measure muscle and […]
Journal Article – “Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults”
by Jennifer H Hwang, DO; Neda Laiteerapong, MD; Elbert S. Huang, MD; David D. Kim, PhDJAMA Health Forum: 2025 Mar 7;6(3):e245586. doi: 10.1001/jamahealthforum.2024.5586. Published March 14, 2025 This research evaluates the cost-effectiveness of four different antiobesity medications compared to lifestyle modification alone for US adults. Using a microsimulation model, the study projected the lifetime health benefits and costs of these treatments for […]